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Introduction As one of the leading causes of maternal mortality worldwide, hypertensive disorders of pregnancy remain
inadequately treated (1). Preeclampsia, a subset of such disorders, occurs in 5% to 8% of pregnancies, threatening to
continue to fulminant eclampsia (1). Preeclampsia is characterized by new-onset maternal hypertension (>140/90 mmHg)
after the 20th week of gestation accompanied by proteinuria (>300 mg/L protein in a 24-hour urine collection) or in
association with thrombocytopenia, impaired liver function, development of renal insufficiency, pulmonary edema, or new-
onset cerebral or visual disturbances (2). Furthermore, it is associated with negative fetal consequences, with fetal growth
restriction (FGR) a common outcome. Newborns with FGR have structural and metabolic abnormalities that compromise
their development (3). Moreover, preeclampsia is associated with increased long-term cardiovascular risk for both the
mother and the child (3, 4). Preeclampsia is distinct in its complex pathophysiology, and the molecular mechanisms are
not understood. Poor placentation, as well as maternal risk factors leading to placental dysfunction, is involved in the
pathogenesis (1). Many factors have been identified as having an involvement in the progression of preeclampsia,
including dysfunction of the renin-angiotensin system (RAS) (5). As the primary effector of the RAS, angiotensin II is a
peptide hormone with vasoconstrictive and inflammatory properties, and forms a major component of blood pressure
homeostasis (6). Angiotensin II is produced by […]
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Introduction
As one of the leading causes of maternal mortality worldwide, 
hypertensive disorders of pregnancy remain inadequately treated 
(1). Preeclampsia, a subset of such disorders, occurs in 5% to 8% 
of pregnancies, threatening to continue to fulminant eclampsia (1). 
Preeclampsia is characterized by new-onset maternal hypertension 
(>140/90 mmHg) after the 20th week of gestation accompanied 
by proteinuria (>300 mg/L protein in a 24-hour urine collection) 
or in association with thrombocytopenia, impaired liver function, 
development of renal insufficiency, pulmonary edema, or new-on-
set cerebral or visual disturbances (2). Furthermore, it is associat-
ed with negative fetal consequences, with fetal growth restriction 
(FGR) a common outcome. Newborns with FGR have structural 
and metabolic abnormalities that compromise their development 
(3). Moreover, preeclampsia is associated with increased long-term 
cardiovascular risk for both the mother and the child (3, 4).
Preeclampsia is distinct in its complex pathophysiology, and 
the molecular mechanisms are not understood. Poor placentation, 
as well as maternal risk factors leading to placental dysfunction, is 
involved in the pathogenesis (1). Many factors have been identified 
as having an involvement in the progression of preeclampsia, includ-
ing dysfunction of the renin-angiotensin system (RAS) (5).
As the primary effector of the RAS, angiotensin II is a pep-
tide hormone with vasoconstrictive and inflammatory properties, 
and forms a major component of blood pressure homeostasis (6). 
Angiotensin II is produced by the successive actions of renin and 
angiotensin-converting enzyme (ACE) on angiotensinogen (AGT) 
and angiotensin I, respectively. AGT M235T and other mutations 
have been associated with increased AGT plasma levels (7), ele-
Preeclampsia, with the hallmark features of new-onset hypertension and proteinuria after 20 weeks of gestation, is a major 
cause of fetal and maternal morbidity and mortality. Studies have demonstrated a role for the renin-angiotensin system 
(RAS) in its pathogenesis; however, small-molecule RAS blockers are contraindicated because of fetal toxicity. We evaluated 
whether siRNA targeting maternal hepatic angiotensinogen (Agt) could ameliorate symptoms of preeclampsia without 
adverse placental or fetal effects in 2 rodent models. The first model used a cross of females expressing human Agt with 
males expressing human renin, resulting in upregulation of the circulating and uteroplacental RAS. The second model induced 
ischemia/reperfusion injury and subsequent local and systemic inflammation by surgically reducing placental blood flow mid-
gestation (reduced uterine perfusion pressure [RUPP]). These models featured hypertension, proteinuria, and fetal growth 
restriction, with altered biomarkers. siRNA treatment ameliorated the preeclamptic phenotype in both models, reduced 
blood pressure, and improved intrauterine growth restriction, with no observed deleterious effects on the fetus. Treatment 
also improved the angiogenic balance and proteinuria in the transgenic model, and it reduced angiotensin receptor activating 
antibodies in both. Thus, an RNAi therapeutic targeting Agt ameliorated the clinical sequelae and improved fetal outcomes in 
2 rodent models of preeclampsia.
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blood pressure, it also reduces fetal pup weights (19). Moreover, 
existing RAS inhibitors negatively impact fetal health and are thus 
contraindicated in pregnancy (21).
We have sought to assess the role of the maternal circulating 
RAS by reduction of maternal hepatic AGT using RNA interference 
(RNAi). RNAi is a clinically validated technology using synthetic 
siRNA to specifically and catalytically reduce gene expression via 
endogenous RNAi machinery (29–31). Conjugation of chemically 
modified siRNA to triantennary N-acetylgalactosamine provides 
for hepatocyte-specific uptake via the asialoglycoprotein receptor 
and stable target suppression (32, 33). We have used such siRNAs 
for evaluating the impact of Agt suppression in models of pre-
eclampsia. As a large molecule with liver-specific targeting, this 
approach may also avoid the fetotoxicity observed with conven-
tional small-molecule RAS inhibitors.
Results
To demonstrate the ability of hAgt-targeting siRNA to silence 
hAGT in our preeclamptic rat model, we investigated human and 
rat Agt mRNA expression levels in maternal liver, kidney, meso-
metrial triangle, placenta, fetal liver, fetal kidney, and fetal brain 
from preeclamptic rats treated with hAgt-targeting siRNA com-
pared with preeclamptic rats treated with luciferase-targeting 
siRNA. Expression analysis showed efficient suppression of hAgt 
mRNA expression in maternal liver. Maternal kidney showed no 
differential hAgt mRNA expression between groups (Figure 1A). 
We confirmed that silencing of hAgt has no impact on rat AGT 
(rAgt) mRNA expression in maternal liver or kidney (Figure 1B). 
Moreover, hAgt mRNA expression in mesometrial triangle as well 
as placenta, fetal liver, fetal kidney, and fetal brain was not sup-
pressed by hAgt-targeting siRNA and suggested that siRNA does 
not cross the placental barrier (Figure 1C). rAgt expression was 
also unaffected by siRNA in mesometrial triangle, placenta, fetal 
kidney, and fetal brain (Figure 1D). By quantifying the antisense 
stand (the active strand) in tissue, we could confirm that the siR-
NA does not appear to be substantially retained in the placenta 
and is not detectable in fetal tissue. siRNA concentrations were 
below the limit of quantification in fetal liver, while maternal liver 
contained high levels of siRNA (Figure 1E). On average, maternal 
liver exposure (as nanograms of antisense strand per gram of tis-
sue) was approximately 266 times greater than that in the placen-
ta, and approximately 31,661 times greater than that observed in 
the fetus (based on lower limit of quantitation), consistent with 
targeted maternal hepatic delivery.
Analysis of serum AGT levels confirmed silencing of hAgt. 
Serum levels of hAGT were clearly diminished in rats treated with 
hAgt-targeting siRNA compared with luciferase-targeting siRNA as 
control (Figure 2A). Furthermore, circulating rAGT was decreased 
in hAgt-targeting siRNA–treated animals (Figure 2B). Investigation 
of circulating angiotensin peptide levels also revealed a significant 
reduction as compared with controls. Angiotensin metabolites Ang 
1-5, Ang 1-7, Ang 1-8, Ang 1-10, Ang 3-7, and Ang 3-8 were decreased 
in animals treated with hAgt-targeting siRNA (Figure 2C).
We then examined the effect of hAgt-targeting siRNA on the pre-
eclamptic phenotype, where we found an impact on the preeclamp-
sia-defining symptoms of hypertension and proteinuria. Radiotele-
metrically measured mean arterial pressure (MAP) was significantly 
vated systolic and diastolic blood pressure, and hypertension (8). 
Conversely, lowering plasma AGT levels via targeting of hepatic 
Agt expression with small interfering RNA (siRNA) or antisense 
oligonucleotides in a rat model of hypertension lowers blood pres-
sure (9). Similarly, liver-specific knockout of Agt in mice confirms 
that liver is the primary source of circulating AGT (10). Although 
Agt mRNA is present in other organs, such as kidney and adipose, 
it appears that the functional angiotensin II stems from circulating 
(liver-derived) AGT (11).
General dysfunction of the RAS in preeclampsia was first 
described by Gant et al., demonstrating hypersensitivity to angio-
tensin II in women before the onset of hypertension during preg-
nancy (12). Subsequent studies have identified elevated levels of 
the type 1 angiotensin receptor (AT1) (13), heterodimerization of 
AT1 with bradykinin receptor B2 (14), and agonistic AT1 autoan-
tibodies (AT1-AA) (15). AGT has also been linked to preeclampsia 
in multiple clinical studies. The AGT M235T mutation, which is 
associated with higher plasma levels of AGT, is associated with 
preeclampsia (16). An oxidized form of AGT was also observed 
to be more prevalent in preeclamptic women than in normo-
tensive maternal controls and to be associated with a 4-fold 
increase in catalytic release of angiotensin I in the presence of 
prorenin receptor (16). Similarly, a mutation in the renin cleav-
age site (L10F) was identified in a patient with preeclampsia. The 
mutation enabled a 2-fold increase in the catalytic efficiency of 
cleavage by renin and a greater than 2-fold increase in the rate of 
angiotensin II formation by ACE (17).
How such perturbations may interact is not fully understood, 
but it is known that AT1-AA can induce angiotensin sensitivity 
(18), possibly through impaired internalization of AT1 (18). Con-
sistent with this, administration of an ACE inhibitor or angioten-
sin II receptor blocker reduces blood pressure in both the reduced 
uterine perfusion pressure (RUPP) model (where AT1-AA are 
present) and the AT1-AA infusion model (19, 20). However, ACE 
inhibitor use is associated with risk of fetal death, FGR, and renal 
abnormalities (21, 22). Moreover, there is a negative relationship 
between use of non–RAS-blocking antihypertensive drugs and 
birth weight (23). In the CHIPS trial, a lower blood pressure target 
was associated with a trend to increased risk of small-for-gesta-
tional-age (SGA) birth (CI, 0.44–1.0) (24). Thus, a fetal-sparing 
antihypertensive, in addition to mitigating the potential role of the 
RAS in preeclampsia, may be beneficial.
A cross of rats or mice bearing human AGT (hAgt) and human 
renin (hRen) has been demonstrated to reproduce much of the 
pathology observed in preeclampsia, including hypertension, pro-
teinuria, FGR, and elevated factors such as AT1 agonistic autoan-
tibodies (15, 25, 26). As both tissue and circulating renin-angioten-
sin systems have been implicated, including uteroplacenta (27), it 
is unclear to what extent these systems contribute to pathology in 
this model (26, 27).
Another animal model of preeclampsia is the reduced uter-
ine perfusion pressure (RUPP) model. In this model, surgically 
induced placental ischemia gives way to hypertension, systemic 
inflammation, oxidative stress, and FGR (28). As with the trans-
genic model above, the RUPP model is associated with alter-
ations in the RAS, including agonistic autoantibodies. Although 
the application of an ACE inhibitor to this model produces lower 
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± 1.89 mmHg luciferase vs. 138.44 ± 1.81 mmHg hAgt RNAi), as well 
as substantially reduced 24-hour urine albumin secretion (18.04 ± 
3.19 mg/d luciferase vs. 2.75 ± 0.56 mg/d hAgt RNAi) (Figure 3B). 
Additionally, renal neutrophil gelatinase–associated lipocalin (Ngal) 
reduced over the course of pregnancy in rats treated with hAgt-tar-
geting siRNA compared with luciferase-targeting siRNA (Figure 
3A). Silencing of hAGT prevented the increase in blood pressure in 
the last trimester of pregnancy (MAP on day 16 of gestation: 156.24 
Figure 1. siRNA does not cross the placental barrier. (A) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on hAgt mRNA expression levels in 
maternal liver and kidney tissue of preeclamptic (PE) rats. hAgt expression was significantly reduced in maternal liver but not in maternal kidney (n = 5 each; 
*P < 0.05; Mann-Whitney test; mean ± SEM). (B) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on rAgt mRNA expression levels in maternal 
liver and kidney tissue of PE rats. rAgt expression was unaffected in maternal liver and kidney by siRNA (n = 5 each; mean ± SEM). (C) Effect of luciferase-tar-
geting siRNA or hAgt-targeting siRNA on hAgt mRNA expression levels in mesometrial triangle, placenta, and fetal tissue in PE rats. hAgt expression was not 
suppressed by hAgt-targeting siRNA in mesometrial triangle, placenta, fetal liver, fetal kidney, or fetal brain. Expression level of hAgt was higher in fetal liver 
of hAgt-targeting versus luciferase-targeting siRNA–treated rats (n = 5 each; *P < 0.05, **P < 0.01; unpaired t test; mean ± SEM). (D) Effect of luciferase- 
targeting siRNA or hAgt-targeting siRNA on rAgt mRNA expression levels in mesometrial triangle, placenta, and fetal tissue of PE rats. rAgt expression was 
unaffected in mesometrial triangle, placenta, fetal kidney, and fetal brain by siRNA. Expression level of rAgt was higher in fetal liver of hAgt-targeting versus 
luciferase-targeting siRNA–treated rats (n = 5 each; **P < 0.01; Mann-Whitney test; mean ± SEM). (E) Distribution of hAgt-targeting siRNA in PE rats after 
treatment. The highest amount of siRNA could be detected in the maternal liver (n = 4), whereas the amount of siRNA was lower in placental compared with 
maternal liver (n = 4; **P < 0.01; 1-way ANOVA with Tukey’s post hoc test; mean ± SEM) and none was detectable in fetal liver (n = 8). LOD, limit of detection.
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geting siRNA–treated animals (0.88 ± 0.02 luciferase vs. 0.73 ± 0.02 
hAgt RNAi). Fetal brain and liver weights were higher in hAgt-target-
ing siRNA–treated rats compared with luciferase-targeting siRNA–
treated rats (Supplemental Figure 2, A and B). Uteroplacental unit 
weight (0.49 ± 0.01 g luciferase vs. 0.61 ± 0.01 g hAgt RNAi) was 
also enhanced by hAgt-targeting siRNA application (Supplemental 
Figure 2C). The numbers of implantation sites and live fetuses were 
similar between the groups, although there was a trend (P = 0.09) 
toward a decrease in number of fetuses that were reabsorbed in 
hAgt-targeting siRNA–treated rats (Supplemental Figure 3).
We next investigated whether silencing of hAgt had an impact 
on trophoblast function and uteroplacental morphology. The area 
of interstitial trophoblast cell invasion into the mesometrial triangle 
was increased in hAgt-targeting siRNA–treated rats compared with 
luciferase-targeting siRNA–treated rats (4.18 ± 0.64 mm2 luciferase 
vs. 5.93 ± 0.45 mm2 hAgt RNAi) (Figure 5, A and B). Histomorpho-
logical analysis revealed no difference in the area of the mesometri-
al triangle (Figure 5C), whereas a significant overall increase of the 
placental area in hAgt-targeting siRNA–treated rats was detected 
mRNA expression was significantly decreased (P < 0.05) in hAgt-tar-
geting siRNA–treated rats (Figure 3C). Serum creatinine and serum 
cystatin C were within the normal range and were not affected by the 
treatment (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI99417DS1).
Improvement of the maternal phenotype was accompanied by 
an improvement of the fetal phenotype. Fetal weights on day 21 of 
gestation were significantly higher in hAgt-targeting siRNA–treat-
ed rats (3.40 ± 0.02 g) compared with luciferase-targeting siRNA–
treated animals (2.64 ± 0.03 g) (Figure 4A). Fetal weight frequen-
cy distribution curves demonstrated that all fetuses treated with 
hAgt-targeting siRNA were above the 10th percentile and the num-
bers of markedly underdeveloped pups were manifestly reduced 
(Figure 4B). Additionally, analysis of the fetuses of dams treated 
with hAGT-targeting siRNA indicated a positive influence on FGR, 
as assessed on the 21st day of pregnancy. The FGR ratio is calcu-
lated by division of the weight of fetal brains by the weight of fetal 
livers (Figure 4C). Application of hAgt-targeting siRNA decreased 
the fetal brain/liver weight ratio in comparison with luciferase-tar-
Figure 2. siRNA against hAgt reduces serum angiotensinogen and angiotensin peptide levels. (A) Effect of luciferase-targeting siRNA or hAgt-targeting 
siRNA on serum hAGT levels in preeclamptic (PE) rats. Serum hAGT concentrations were significantly reduced in hAgt-targeting siRNA–treated (n = 9) 
versus luciferase-targeting siRNA–treated (n = 5) rats (**P < 0.01; unpaired t test; mean ± SEM). (B) Effect of luciferase-targeting siRNA or hAgt-targeting 
siRNA on serum rAGT levels in PE rats. Serum rAGT concentrations were significantly reduced in hAgt-targeting siRNA–treated (n = 9) versus lucifer-
ase-targeting siRNA–treated (n = 5) rats (***P < 0.001; unpaired t test; mean ± SEM). (C) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA 
on circulating angiotensin (Ang) peptide levels in PE rats. Serum peptide concentrations of Ang 1-5, Ang 1-7, Ang 1-8, Ang 1-10, and Ang 3-8 were lower in 
hAgt-targeting siRNA–treated (n = 9) versus luciferase-targeting siRNA–treated (n = 5) rats (**P < 0.01, ***P < 0.001; Mann-Whitney test or unpaired t 
test; mean ± SEM). Serum peptide concentrations of Ang 1-9, Ang 2-7, Ang 2-8, Ang 2-10, and Ang 3-7 were unaffected.
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genic and antiangiogenic factors, such as placental growth factor 
(PLGF) and soluble fms-like tyrosine kinase-1 (sFLT-1), since both 
factors are altered in preeclampsia (34). As shown in Figure 7A, 
serum PLGF concentration was increased in hAgt-targeting siR-
NA–treated rats compared with luciferase-targeting siRNA–treat-
ed rats, whereas serum sFLT-1 (Figure 7B) was reduced. Conse-
quently, the serum sFLT-1/PLGF ratio was decreased (Figure 7C) 
with hAgt suppression in the transgenic preeclamptic rat model.
Next, we examined the effect of silencing maternal rAgt on 
blood pressure, uteroplacental unit, and fetal growth in the RUPP 
model of preeclampsia in rats. Investigation of rAgt mRNA expres-
sion levels in maternal liver showed suppression of rAgt mRNA, 
indicating efficient gene silencing in maternal liver (Figure 8A) in 
treated rats. Maternal kidney showed no difference in rAgt mRNA 
expression between groups (Figure 8B). Moreover, rAgt mRNA 
expression in mesometrial triangle as well as placenta, fetal liver, 
fetal kidney, and fetal brain was not suppressed by rAgt-targeting 
siRNA in treated rats (Figure 8, C–G).
(28.12 ± 1.59 mm2 luciferase vs. 33.79 ± 1.31 mm2 hAgt RNAi) (Figure 
5D). This increase was due to the enlargement of the labyrinth zone 
of the placenta, while the trophospongium area remained unal-
tered between hAgt-targeting siRNA–treated and luciferase-target-
ing siRNA–treated rats (Figure 5, E and F). Analysis of spiral artery 
remodeling of the uteroplacental unit revealed an improvement by 
treatment with hAgt-targeting siRNA, suggesting improved placen-
tal perfusion (Supplemental Figure 4). Furthermore, we examined 
the macrophages in the uteroplacental unit. Immunohistological 
analysis indicated an increase in number of macrophages in the 
uteroplacental unit in hAgt-targeting siRNA–treated rats compared 
with luciferase-targeting siRNA–treated rats (Figure 5, G and H).
Since this preeclampsia model features autoantibodies direct-
ed against angiotensin II receptor type 1 (AT1-AA), we next inves-
tigated whether silencing of hAgt could influence AT1-AA levels 
(15, 26). Application of hAgt-targeting siRNA reduced the pres-
ence of AT1-AA (Figure 6). Furthermore, we examined whether 
silencing of hAgt had an impact on the balance between proangio-
Figure 3. siRNA against hAgt reduces mean arterial pressure and albuminuria. (A) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on mean arterial 
pressure (MAP) in preeclamptic (PE) rats. MAP measured by telemetry was reduced in hAgt-targeting siRNA–treated (n = 9) compared with luciferase-target-
ing siRNA–treated (n = 5) PE rats (*P < 0.01, #P < 0.5; 2-way ANOVA with Bonferroni’s post hoc test; mean ± SEM). (B) Effect of luciferase-targeting siRNA or 
hAgt-targeting siRNA on albuminuria in PE rats. Albuminuria was normalized by hAgt-targeting siRNA treatment (n = 9) compared with luciferase-targeting 
siRNA treatment (n = 10) (***P < 0.001; unpaired t test; mean ± SEM). (C) Effect of luciferase-targeting siRNA or hAgt-targeting siRNA on Ngal mRNA expression 
levels in maternal liver and kidney tissue of PE rats. Ngal expression was significantly reduced in maternal kidney of hAgt-targeting versus luciferase-targeting 
siRNA–treated rats (n = 5 each; *P < 0.05; Mann-Whitney test; mean ± SEM).
Figure 4. siRNA against hAgt improves fetal outcome. (A) Fetal weights were increased after application of hAgt-targeting siRNA (n = 102) versus lucif-
erase-targeting siRNA (n = 80) (***P < 0.001; unpaired t test; mean ± SEM). (B) Frequency distribution curves for individual pups. A rightward shift of the 
curve for pups from the hAGT-targeting siRNA group (gray solid curve) compared with the luciferase-targeting siRNA group (black dashed curve) illustrates 
the improved fetal outcome. Vertical dashed line denotes the 10th percentile of luciferase-targeting siRNA–treated PE fetal weights. (C) Fetal growth 
restriction is shown as the ratio between fetal brain and liver weights. Application of hAgt-targeting siRNA (n = 49) decreased the fetal brain/liver weight 
ratio compared with luciferase-targeting siRNA (n = 44) (***P < 0.001; Mann-Whitney test; mean ± SEM).
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Figure 5. siRNA against hAgt improves placenta morphology. (A) Extension of trophoblast cell invasion was measured as the area of the meso-
metrial triangle invaded by trophoblast cells. This area was significantly increased in hAgt-targeting siRNA–treated (n = 9) preeclamptic (PE) rats 
compared with luciferase-targeting siRNA–treated (n = 10) rats (*P < 0.05; unpaired t test; mean ± SEM). (B) Representative pictures of cytoker-
atin-stained midsagittal mesometrial triangle (MT) and placental (P) tissue sections used to carry out the histomorphological analysis. Different 
zones of the placenta are marked: T, trophospongium; L, labyrinth. (C) The area of the mesometrial triangle was not different between lucifer-
ase-targeting siRNA– and hAGT-targeting siRNA–treated PE rats (mean ± SEM). (D) The overall size of the placenta was increased in hAgt-targeting 
siRNA–treated (n = 9) PE rats compared with luciferase-targeting siRNA–treated (n = 10) rats (*P < 0.05; unpaired t test; mean ± SEM). (E) The area 
of the trophospongium was not changed in hAgt-targeting siRNA–treated (n = 9) PE rats compared with luciferase-targeting siRNA–treated (n = 
10) rats (mean ± SEM). (F) The area of the labyrinth zone of placentas of hAgt-targeting siRNA–treated (n = 9) PE rats was enhanced in compar-
ison with luciferase-targeting siRNA–treated (n = 10) rats (*P < 0.05; unpaired t test; mean ± SEM). (G) Representative pictures of CD68-stained 
uteroplacental unit tissue sections. (H) The number of macrophages was increased in hAgt-targeting siRNA–treated (n = 9) PE rats compared with 
luciferase-targeting siRNA–treated (n = 9) rats. **P < 0.01; unpaired t test.
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MAP was elevated in RUPP versus normal pregnant (NP) 
rats (135.3 ± 5.3 vs. 101.4 ± 4.5 mmHg). Treatment of RUPP rats 
with rAgt-targeting siRNA led to a reduction in MAP (117.0 ± 
4.9 mmHg) in comparison with untreated RUPP rats, but there 
was no significant change in NP rats treated with rAgt-targeting 
siRNA (rAgt RNAi; 92.1 ± 2.9 mmHg) compared with untreated 
NP rats (Figure 9A). As has been previously described in the RUPP 
model, we could not detect albuminuria (Figure 9B). Average fetal 
weights by group were 2.30 ± 0.09 g (NP), 1.89 ± 0.10 g (RUPP), 
2.38 ± 0.09 g (NP [rAgt RNAi]), and 2.12 ± 0.06 (RUPP [rAgt RNAi]) 
(Figure 9C). A 1-way ANOVA with Tukey’s post hoc test indicated 
a significant reduction in pup weights in RUPP compared with NP, 
but not NP (rAgt RNAi) or RUPP (rAgt RNAi), indicating that admin-
istration of siRNA to RUPP rats ameliorated the decrease in fetal 
weight. Although the effect of siRNA treatment on fetal weights 
in the RUPP group did not reach significance in comparison with 
untreated RUPP, the weights were also no longer significantly dif-
ferent from NP. Furthermore, the fetal brain/liver weight ratio as a 
measure of FGR was increased by the RUPP procedure, but reduced 
with the addition of the siRNA. Administration of rAgt-targeting 
siRNA to RUPP rats thus improves the FGR (Figure 9D). However, 
uteroplacental weights were not affected by rAgt-targeting siRNA 
treatment in the RUPP model (Supplemental Figure 5A). The num-
bers of implantation sites, live fetuses, and fetuses that were reab-
sorbed were similar between untreated and siRNA-treated NP and 
RUPP rats (Supplemental Figure 5, B–D).
As with the transgenic model, the RUPP procedure induces 
the production of activating autoantibodies against the AT1. Simi-
lar to the results in the transgenic rat model, silencing of rAgt leads 
to a normalization of activity (Supplemental Figure 6). Neither the 
RUPP procedure nor suppression of rAgt by siRNA had an impact 
on the balance between proangiogenic (PLGF) and antiangiogenic 
(sFLT-1) factors (Supplemental Figure 7).
Next, we looked in more detail into whether the rAgt siRNA 
treatment has any negative consequences for the fetus. We treated 
NP rats with rAgt siRNA, using the same regimen as with the RUPP 
model, for comparison with untreated NP controls. We performed 
micro-CT (μCT) of the skull of the fetus at the end of the pregnancy 
to analyze calvarial morphology. We could not detect any changes 
in the fetal skull, as both width and length were unchanged (Fig-
ure 10, A–C). Also, the weight and volume of fetal brain at the end 
of gestation and in 3-week-old offspring showed no effect of rAgt 
siRNA (Supplemental Figure 8, A–D). Moreover, we analyzed the 
expression of different genes that are important during brain devel-
opment, such as adenosine receptor 1 (Adora, neuromodulation), 
synaptophysin (Syp1, synaptic plasticity), neuregulin-1 (Nrg1, neuro-
genesis), and neuropilin-1 (Nrp1, axonal growth) (35, 36), and could 
not detect an influence of siRNA treatment in the fetal brain (Sup-
plemental Figure 8, E–H). Next, we examined the impact of the rAgt 
siRNA treatment on renal development in the fetus. We could not 
detect any difference in kidney weight/body weight ratio in 3-week-
old offspring from dams that were treated with siRNA (Figure 10D). 
The histological analyses of offspring kidney revealed no alteration 
in renal morphology by the siRNA treatment (Figure 10, E–G). 
Additionally, we analyzed the expression of different genes that are 
important during kidney development, including octamer-binding 
transcription factor 4 (Oct4, renal stem/progenitor cells), paired 
box gene 2 (Pax2, intermediate mesoderm), sine oculis–related 
homeobox 2 (Six2, nephron progenitor cells), and homeobox pro-
tein B7 (HoxB7, ureteric bud) (37, 38), and could not detect an influ-
ence of siRNA treatment in fetal kidney at the end of pregnancy or 
in 3-week-old offspring (Supplemental Figure 9). We looked next at 
the effect of the siRNA treatment on the fetal heart. We could not 
detect any difference in heart weight/body weight ratio in fetuses 
and offspring from dams that were treated with siRNA (Supplemen-
tal Figure 10, A and B). To investigate whether a persistent patent 
ductus arteriosus occurs in the fetus and offspring, we determined 
circulating prostaglandin E2 (PGE2) levels. It has been shown that 
prostaglandins maintain the patency of the ductus arteriosus in the 
fetus, and some studies have found that preterm infants with patent 
ductus arteriosus have significantly higher levels of PGE2 (39–41). 
We could see no differences in circulating PGE2 levels in either the 
fetus or the offspring with siRNA treatment (Supplemental Figure 
10, C and D). Finally, we studied offspring lungs to see whether 
there was pulmonary hyperplasia due to siRNA treatment. We 
could not detect any difference in lung weight/body weight ratio in 
3-week-old offspring from dams that were treated with siRNA (Sup-
plemental Figure 10E). As a morphometric index, we determined 
the mean linear intercept (Lm) as an index of alveolar size. The 
mean linear intercept in offspring lung was not affected by siRNA 
treatment during pregnancy (Supplemental Figure 10, E–H).
Discussion
In the present study we have demonstrated that RNAi therapeutics 
targeting Agt ameliorated the preeclamptic phenotype in 2 animal 
models of preeclampsia. These models reflect different approach-
es to producing the preeclamptic phenotype in rodents. With this 
Figure 6. siRNA against hAgt decreases the concentration of angio-
tensin II receptor type 1 autoantibodies (AT1-AA) in the serum of 
preeclamptic rats. Isolated rat neonatal cardiomyocytes were treated 
in vitro with IgG from luciferase-targeting siRNA–treated (n = 5) or 
hAgt-targeting siRNA–treated (n = 8) preeclamptic (PE) rats. Data are 
presented as an increase in beating rate of cardiomyocytes after treat-
ment with IgG compared with baseline. Administration of AT1 receptor 
blocker (losartan) (n = 5 each) was used to show that the effect is medi-
ated via the AT1 receptor (***P < 0.001; 1-way ANOVA with Tukey’s post 
hoc test; mean ± SEM).
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demonstrate placental insufficiency with severe FGR, resem-
bling early-onset preeclampsia. In the first model, silencing of 
hAgt enhances the area of interstitial trophoblast cell invasion, 
as well as the placenta area. AT1 autoantibodies, reported to play 
a pathological role in preeclampsia (44, 45), were significantly 
reduced. The sFLT-1/PLGF ratio, considered not only to play a 
role in pathophysiology but also to be a potential biomarker of 
disease progression, was improved as well (46).
The improvement of both the maternal and fetoplacental phe-
notypes in the transgenic rat model confirms the role of the cir-
culating RAS in the progression of the disease in this model, and 
indicates the significant impact circulating factors can have on the 
fetus and placenta. Further studies are necessary to determine 
whether reduction of maternal AGT levels leads to a reduction 
of oxidative stress or other known features of the human condi-
tion not presently evaluated (5). How maternal AGT and its active 
metabolites affect placental development is a key question.
Although blood pressure was not fully normalized in the present 
model, neither were angiotensin metabolites fully normalized to 
levels observed in normotensive pregnant rats. Treatment reduced 
angiotensin II by 90% in comparison with control transgenic ani-
mals, but angiotensin II remained elevated over that in normo-
tensive pregnant controls. Considering AGT, treatment reduced 
hAGT to 5% of that of control animals; rAGT, though not targeted 
by the siRNA, was also reduced to nearly half that of control trans-
genic animals. Absent any change in transcription, this suggests an 
increase in conversion of rAGT to angiotensin I. Given that angio-
tensin II is known to inhibit renin secretion (47), near-elimination of 
angiotensin II derived from the human isoform may have resulted 
in a derepression of rat renin and subsequently enhanced angioten-
sin production from the rat AGT isoform.
Although no animal model of preeclampsia fully recapitu-
lates the clinical phenotype, one important aspect of our results 
and the transgenic rat model in particular is the clear translation 
of the intervention in rats to the human situation. In patients, 
we aim for a modest reduction in blood pressure (to a systol-
ic blood pressure of ~140–160 mmHg) without compromis-
ing effects on the fetus, as excessive blood pressure lowering 
is associated with FGR (23). Here, we have similarly reduced 
blood pressure and indeed enhanced fetal outcomes (such as 
technique, we were able to selectively modulate maternal RAS sig-
naling, while preserving the fetal RAS in both models. Similar lev-
els of Agt suppression by siRNA have been described previously, 
in nongravid spontaneously hypertensive rats (42). In that study, 
approximately 98% suppression of Agt by RNAi was well tolerat-
ed and produced substantial blood pressure lowering. Thus, while 
means of reversing siRNA pharmacology exist (43), as presently 
evaluated, they do not appear necessary. However, further stud-
ies are necessary to assess whether conventional means of raising 
blood pressure remain effective with Agt suppression, particularly 
in the context of pregnancy.
In the transgenic model, silencing of hAgt only in the mater-
nal liver decreased the elevated AGT and angiotensin metabolite 
levels in the tissue and circulating renin-angiotensin systems, 
leading to a reduction of blood pressure and urinary albumin 
excretion. We improved FGR, reversing the brain-sparing phe-
nomenon and demonstrating increased brain size, indicating an 
improved fetal development. Upregulation of hAgt and rAgt was 
noted in the fetus. The cause and the consequences of Agt upreg-
ulation in the fetal liver are unclear and deserve further investiga-
tion; however, this was not observed in the RUPP model and, in 
view of improvements in the fetus, may not be deleterious.
The RUPP model confirmed the principal findings of the 
first model, including improved FGR and increased fetal brain 
size, in a model that is not explicitly driven by the RAS. Criti-
cally, fetal weights were not reduced in the treated group, 
and blood pressure was lowered. Moreover, a detailed assess-
ment of brain, lung, kidney, and heart in fetus and offspring of 
rAgt-treated dams revealed no deleterious effects. In particular, 
siRNA treatment did not lead to renal tubular dysgenesis, cal-
varial or pulmonary hypoplasia, or persistent patent ductus arte-
riosus. In summary, we can say that in all studies regarding the 
impact of siRNA treatment on the fetus, we did not detect any 
negative fetal consequences of the treatment. Thus, through use 
of a maternal-targeted agent, we believe we have uncoupled the 
preeclamptic treatment conundrum: that blood pressure reduc-
tion is associated with a reduction in fetal weight.
Our studies give further insight into the potential benefits 
of blocking the maternal RAS. The first model acts by upregu-
lation of the circulating and uteroplacental RAS (15). The dams 
Figure 7. siRNA against hAgt alters proangiogenic and antiangiogenic factors. (A) Serum PLGF concentrations were increased in hAgt-targeting siRNA–treat-
ed (n = 8) versus luciferase-targeting siRNA–treated (n = 10) rats (*P < 0.05; unpaired t test; mean ± SEM). (B) Serum sFLT-1 concentrations were reduced in 
hAgt-targeting siRNA–treated (n = 8) versus luciferase-targeting siRNA–treated (n = 10) rats (*P < 0.05; unpaired t test; mean ± SEM). (C) The sFLT-1/PLGF ratio 
was decreased in hAgt-targeting siRNA–treated (n = 8) versus luciferase-targeting siRNA–treated (n = 10) rats (**P < 0.01; unpaired t test; mean ± SEM).
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Figure 8. siRNA does not suppress extrahepatic or fetal Agt in normal pregnant 
or RUPP rats. (A) rAgt expression was reduced in maternal liver in rAgt-targeting 
siRNA–treated normal pregnant (NP; n = 6) and RUPP (n = 6) rats compared with 
the untreated NP (n = 5) and RUPP (n = 5) groups (***P < 0.001; 1-way ANOVA 
with Tukey’s post hoc test; mean ± SEM). (B–D) rAgt expression was not altered 
in maternal kidney (B), mesometrial triangle (C), or placenta (D) in rAgt-targeting 
siRNA–treated NP (n = 6) and RUPP (n = 6) rats compared with the untreated NP (n 
= 5) and RUPP (n = 5) groups (mean ± SEM). (E–G) rAgt mRNA expression in fetal liv-
er (E), fetal kidney (F), and fetal brain (G) was not downregulated by rAgt-targeting 
siRNA in treated rats (NP n = 6, NP [rAgt RNAi] n = 5, RUPP n = 6, RUPP [rAgt RNAi] 
n = 6; mean ± SEM).
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of siRNA was given, in the middle of gestation, to avoid potential 
complications with the RUPP procedure (such as hypotension). 
Given the expected delay between siRNA dosing and onset of 
action (9), blood pressure reduction may not have been maximal 
at time of assay. Thus, optimizing study parameters further could 
yield further improvements in outcomes.
Despite exposure of the dams to the siRNA at relatively high 
doses, siRNA in fetal liver was below the limit of detection. These 
data are consistent with available data on placental transfer indi-
cating limited transfer for large negatively charged molecules 
without active transport (48). Moreover, the GalNAc3-conjugat-
ed siRNA requires receptor-mediated uptake by the asialoglyco-
protein receptor, which is not expressed appreciably in fetal liver 
until near delivery (49, 50). Thus, the use of a maternal liver-tar-
geted isoform-specific siRNA in a transgenic model allows the 
reduced FGR). Moreover, we have confirmed the principal find-
ings in an orthogonal model of preeclampsia, the RUPP model. 
In the present study, complete normalization of blood pressure 
in the transgenic model may not have been achieved owing to 
inadequate Agt suppression (including over time), or perhaps 
to a rise in rat renin (as suggested by reduced full-length rAGT 
in circulation), offsetting the impact of hAgt lowering. Further 
studies are warranted to look at fetal outcomes if blood pres-
sure is fully normalized with Agt RNAi.
The second model is a surgical model that induces ischemia/
reperfusion injury and subsequent local and systemic inflamma-
tion restriction (28). This model is performed after placentation 
has taken place, and FGR, while present, is markedly less than in 
the first model. Thus, the second model represents more a model 
of late-onset preeclampsia. In the RUPP model, only a single dose 
Figure 9. Administration of rAgt siRNA to RUPP rats blunts the increase in blood pressure and prevents a decrease in fetal weights. (A) MAP was 
reduced in rAgt-targeting siRNA–treated RUPP rats (n = 7) compared with untreated RUPP rats (n = 6), and unchanged in NP rats treated with rAgt-target-
ing siRNA (n = 7) compared with untreated NP rats (n = 7) (*P < 0.05, **P < 0.01, ***P < 0.001; 1-way ANOVA with Tukey’s post hoc test; mean ± SEM). (B) 
Albuminuria was not observed in the RUPP model, and no differences could be detected between rAgt-targeting siRNA–treated rats and untreated rats 
(NP n = 11, NP [rAgt RNAi] n = 8, RUPP n = 11, RUPP [rAgt RNAi] n = 9; mean ± SEM). (C) Fetal weights were decreased in response to placental ischemia 
in untreated RUPP rats (n = 6) compared with untreated NP rats (n = 7) and NP rats treated with rAgt-targeting siRNA (n = 7); however, the application of 
rAgt-targeting siRNA to RUPP rats (n = 7) ameliorated the decrease in fetal weight (*P < 0.05, **P < 0.01; 1-way ANOVA with Tukey’s post hoc test; mean 
± SEM). (D) Fetal brain/liver weight ratios were increased in untreated RUPP (n = 6) compared with untreated (n = 7) and treated rAgt-targeting siRNA–
treated (n = 7) NP rats. Administration of rAgt-targeting siRNA to RUPP rats (n = 7) reduced the fetal brain/liver weight ratio (*P < 0.05, **P < 0.01, ***P < 
0.001; 1-way ANOVA with Tukey’s post hoc test; mean ± SEM).
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The interplay between AT1-AA and endogenous angiotensin 
II is unclear, as in vivo studies evaluating the impact of AT1-AA 
infusion have generally been in the context of normal endoge-
nous angiotensin II levels (15, 44, 45). Our observation of reduced 
AT1-AA suggests that angiotensin-mediated signaling impacts 
the production of these autoantibodies. It has been demonstrat-
ed that antibodies generated against the known epitope required 
infusion of angiotensin II to recapitulate the disease model (53). 
Additionally, administration of an ACE inhibitor in the infusion 
model reduced blood pressure by a greater amount in infused ani-
mals than in NP animals, indicating that the endogenous ligand 
remains active and may act synergistically with AT1-AA (19). How 
the continued activity of angiotensin II relates to the production 
and activity of AT1-AA requires further elucidation.
Targeting the RAS in a maternal-specific manner may be an 
effective treatment for preeclampsia, as demonstrated in the pres-
ent models. The ability to lower maternal blood pressure while 
separation of primary and secondary effects of the treatment. 
hAGT expression in the placenta was unchanged, with a trend 
toward upregulation of rAGT. Upregulation of both isoforms in 
fetal liver, while an unexpected result, may reflect a response to 
altered hemodynamics. Consistent with this upregulation, we 
observed an increase in trophoblast invasion, a process known 
to be stimulated by local angiotensin II (26). Macrophage pres-
ence was also increased. The role of macrophages in preeclamp-
sia is complex, and the physiological impact depends on the 
class of macrophages present (51). M2 macrophages are thought 
to mediate tolerance as well as trophoblast invasion (52), both 
processes relevant to preeclampsia. Although the identity of the 
macrophages induced by treatment in the present study was not 
assessed, these data warrant further evaluation of angiotensin- 
mediated alterations in the macrophage population in preeclamp-
sia. These findings may provide a mechanism for the observed 
larger placenta size in treated animals as well as reduced FGR.
Figure 10. rAgt siRNA has no negative impact on calvarial and renal morphology of the fetus. (A) Measurement of fetal skull width showed no difference in 
pups from untreated and siRNA-treated NP rats (n = 6 each; mean ± SEM). (B) Fetal skull length was also unchanged in pups from untreated and siRNA-treat-
ed NP rats (n = 6 each; mean ± SEM). (C) Representative micro-CT images of fetal rat skulls. (D) The kidney weight/body weight ratio of 3-week-old offspring 
was not changed between untreated and siRNA-treated groups (n = 10 each; mean ± SEM). (E) Number of glomeruli in 3-week-old offspring kidneys was 
not influenced by siRNA treatment (n = 10 each; mean ± SEM). (F) Representative images of Masson’s trichome–stained kidney sections of offspring from 
untreated and siRNA-treated NP rats. (G) Representative images of H&E-stained kidney sections of offspring from untreated and siRNA-treated NP rats.
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Methods
Further information can be found in Supplemental Methods, available 
online with this article; https://doi.org/10.1172/JCI99417DS1.
siRNA synthesis. siRNAs targeting TGAGAACAAAAATTG-
GGTTTTAA in hAGT (NM_00029.3) and GAGCTATCCTGGG-
CAAAAATCAA in rAGT (NM_134432.2) were prepared as chemical-
ly modified triantennary GalNAc conjugates as described previously 
(33). Duplexes were synthesized on controlled pore glass (CPG) solid 
support on a MerMade 192 synthesizer at 1 μmol scale. The synthesis 
of AGT sequences was performed using solid-supported oligonucle-
otide methodology and standard phosphoramidite chemistry. Amidite 
solutions were prepared at 0.1 M concentration, and ethyl thiotetra-
zole (0.6 M in acetonitrile) was used as activator. Deblock solution 
(3% dichloroacetic acid in dichloromethane), oxidizer solution (50 
mM iodine in 9:1 pyridine/water mixture), and capping reagent (A + B) 
solutions were prepared according to reported procedures (68). Sense 
and antisense single strands were chemically modified at selected 
sites with either 2′-O-methyl or 2′-F nucleosides. Sense strand was syn-
thesized on a solid support loaded with a triantennary GalNAc moiety, 
while the antisense sequence was synthesized on a solid support load-
ed with 2′-OMe A.
The synthesized sequences were cleaved and deprotected in 
96-well plates, using aqueous methylamine reagent (25–45 minutes 
on column to cleave the sequences from the solid support, filtered, 
followed by continued incubation of the crude oligonucleotide filtrate 
at 60°C for 30 minutes). After centrifugation and decanting of the sol-
vents, the pellet was isolated and resuspended in 0.2 M sodium acetate 
buffer. The single strands were analyzed by liquid chromatography–
mass spectrometry to confirm the identity, by UV for quantification, and 
by ion exchange chromatography to determine purity.
Purification and desalting. Resuspended Agt single strands were 
desalted using an AKTA Purifier system equipped with a Sephadex 
G25 column. The process was run at ambient temperature. Sample 
injection and collection were performed in 96-well plates (1.8-mL 
deep well plates). A single peak for each sequence was collected in the 
eluent. The desalted AGT sequences were analyzed for concentration 
(by UV measurement at A260) and purity (by ion exchange HPLC). 
The complementary single strands were then combined in a 1:1 stoi-
chiometric ratio to form siRNA duplexes.
Animals. Female Sprague-Dawley rats harboring the hAgt 
gene [TGR(hAogen)L1623] were mated with male Sprague-Daw-
ley rats bearing the human renin (hRen) gene [TGR(hRen)L10J] 
to produce a model of preeclampsia (PE) in the dams (69). 
These pregnant dams develop hypertension on day 13 of preg-
nancy (plug-recognition day is assigned as day 1) and albumin-
uria (26). Mean blood pressure was continuously recorded by 
radiotelemetry. The implantation of radiotelemetry pressure trans-
ducers (TA11PA-C20, Data Sciences International, La Jolla, Cal-
ifornia, USA) was performed 10 days before mating as described 
previously (26). Twenty-four-hour urine samples were collected in 
metabolic cages at day 17/18 of gestation.
Transgenic dams were randomly assigned to 2 experimental 
groups: hAgt-targeting siRNA or luciferase-targeting siRNA as con-
trol. Beginning on day 3 of gestation, transgenic hAgt dams were 
dosed s.c. with 10 mg/kg siRNA every third day through gestation 
day 15. This regimen was chosen to maximize exposure, for assess-
ment of fetal effects and exposure.
supporting fetal growth contrasts with existing agents. Drugs 
such as methyldopa, labetolol, and nifedipine neither address the 
pathophysiology of preeclampsia, nor support fetal growth. As a 
result, their use presents a dilemma for physicians who need to 
balance the health of the mother and the needs of the growing 
fetus (23). One important aspect of our results is the relevance to 
the human situation. In patients we aim for a modest reduction 
in blood pressure (to 140–160 mmHg systolic blood pressure) 
without compromising effects on the fetus. Further studies are 
warranted, however, to assess fetal outcomes if blood pressure 
is normalized. In contrast to antihypertensives currently used in 
pregnancy, studies have indicated a role for AGT and the RAS in 
preeclampsia pathophysiology. Particularly relevant is the finding 
by Ward et al. linking polymorphism associated with higher angio-
tensin II levels with risk for preeclampsia (16). Other research has 
demonstrated elevated AT1 levels and potentiated AT1-mediated 
signaling (12–14, 54). Angiotensin II–mediated signaling has been 
described to stimulate many pathways implicated in preeclamp-
sia (55). For example, application of agonistic AT1 autoantibodies 
has been observed to result in increased levels of NADPH oxidase 
in vascular smooth muscle cells (VSMCs) and trophoblasts (56), 
elevated sFLT-1 in pregnant mice (45), increased tissue factor 
activity in VSMCs (57), elevated endothelin in pregnant rats (58), 
and promotion of inflammation in pregnant mice by stimulation 
of TNF-α (59). Notably, AT1-AA can induce angiotensin sensitiv-
ity (53), possibly through impaired internalization of AT1 (60). It 
also appears that endogenous angiotensin plays a role; for exam-
ple, enalapril has been observed to blunt the hypertensive effect 
of AT1-AA in rats (58), while losartan blocks elevation of sFLT-1 
in the RUPP model (61). More generally, the associated signaling 
pathways downstream of AT1 activation have also been defined 
(62). Given the lack of fetal exposure to the siRNA in the present 
study, these findings support the further investigation of RNAi 
therapeutics as a potential treatment for preeclampsia.
Investigational RNAi therapeutics are a clinically validated 
class of molecules using both targeted delivery and gene-specific 
silencing. Multiple clinical studies are currently under way across a 
variety of diseases, including hereditary ATTR amyloidosis, hyper-
cholesterolemia, and hemophilia (63–66). Such clinical programs 
share a common targeted delivery to the liver. Delivery of RNAi 
therapeutics via the asialoglycoprotein receptor is highly hepato-
cyte-specific (32). AGT is predominantly derived from hepatocytes 
(9, 10) and, as the progenitor of the RAS, has widespread effects on 
physiology (67). As preeclampsia manifests with both maternal and 
fetal pathology, a therapeutic approach that mitigates the well-de-
scribed risk of hypertension, reduces the RAS-mediated pathology, 
and does not impede the fetal or uteroplacental RAS may be bene-
ficial to patients.
We have demonstrated the pivotal role maternal hepatic AGT 
plays in the progression of preeclampsia in 2 rodent models. Given 
the differences in disease pathophysiology as well as placentation 
between rodents and the human condition, it is unclear how directly 
translatable these findings are. However, supported by the appar-
ent lack of placental transfer, future studies may seek to extend 
these findings. Critically, further studies are necessary to determine 
whether such a correction of the disease phenotype can be obtained 
if treatment is begun in the symptomatic phase.
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line with a QTRAP-4000 mass spectrometer (AB Sciex) operated in 
the MRM mode using dwell times of 25 milliseconds at a cone voltage 
of 4000 V and a source temperature of 300°C. For each peptide and 
corresponding internal standards, 2 different mass transitions were 
measured. Ang II peptide concentrations were calculated by relating of 
endogenous peptide signals to internal standard signals.
mRNA isolation and real-time RT-PCR. Total mRNA was iso-
lated using QIAzol lysis reagent and Qiagen RNeasy Mini Kit (Qia-
gen) with on-column deoxyribonuclease I step (Qiagen) according 
to the manufacturer’s protocol. Two micrograms of mRNA was 
reverse-transcribed into cDNA using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Real-time PCR was detected 
on an ABI 7500 Fast Sequence Detection System (Applied Biosyste-
ms) and analyzed by 7500 Fast System Software (Applied Biosyste-
ms). Primers and probes (Supplemental Table 1) were designed with 
PrimerExpress 3.0 (Applied Biosystems) and synthesized by Biotez.
Immunohistochemistry and histochemistry. Rat uteroplacental units 
were fixed in buffer as described earlier (26), truncated from 2 lateral 
placental parts, and embedded in paraffin. Consecutive sections were 
stained for a trophoblast cell marker (cytokeratin [clone MNF116]; 
M0821, DAKO), a smooth muscle cell marker (α-actin [clone 1A4]; 
M0851, DAKO), and CD68, a marker for monocytes and macrophages 
(clone ED1; MCA341R, AbD Serotec). Sections were visualized on a Zeiss 
Axio Imager M2 microscope fitted with an AxioCamHRc camera (Zeiss) 
using ×10 magnification. On cross sections of the most central part of the 
uteroplacental unit, areas (placental area, mesometrial triangle area, and 
interstitial trophoblast cell invasion into mesometrial triangle) were calcu-
lated using AxioVision software (Zeiss). Actin staining was used to set the 
border between mesometrial triangle and myometrium. Interstitial tro-
phoblast cell invasion into mesometrial triangle was calculated as the area 
of trophoblast cells in the mesometrial triangle. The number of macro-
phages was determined by image analysis using ImageJ (NIH). Masson’s 
trichrome staining of the uteroplacental unit was performed using stan-
dard protocols. The whole stained sections of the uteroplacental unit were 
imaged by a Pannoramic MIDI II BF/FL high-speed slide scanner (3DHIS-
TECH Ltd.), saved, and evaluated offline in a blinded manner using Case-
Viewer analysis software (3DHISTECH Ltd.). We analyzed 9 uteroplacen-
tal unit sections of each group from 6 luciferase-targeting siRNA–treated 
PE rats and 9 hAGT-targeting siRNA–treated PE rats at gestational day 
21. On average, there were 57 vessels in the luciferase-targeting siRNA–
treated group and 97 vessels in the hAGT-targeting siRNA–treated group. 
For the interpretation of vascular remodeling of spiral arteries, the outer 
diameter (OD) and luminal diameter (LD) of each vessel were measured 
at the point of the largest OD using a Pannoramic Viewer (3DHISTECH 
Ltd.). The ratio of LD to OD was used to compare the proportionate ves-
sel wall thickness of the spiral arteries in the mesometrial triangle. Mas-
son’s trichrome and H&E stainings of the kidney sections were performed 
using standard protocols. For the interpretation of renal morphology, the 
number of glomeruli was counted, and fibrosis, tubular dysgenesis, and 
glomerular endotheliosis were evaluated using a Pannoramic Viewer 
(3DHISTECH Ltd.). H&E staining of the lung sections was performed 
using standard protocols. To measure the mean linear intercept (Lm), as 
an index of alveolar size, we did a simple point and intersection counting 
in images of H&E-stained lung sections of 3-week-old offspring using a 
suitable coherent test line system with unit length d — that is, counting 
points hitting airspaces, P(airspace), and intersections of a test line system 
with alveolar surface, I(a), to obtain Lm = 2 × d × P(airspace)/I(a) (71).
The RUPP procedure is a well-established model for studying the 
link between placental ischemia and hypertension in the pregnant rat 
and has been described in detail previously (70). First timed pregnant 
Sprague-Dawley rats purchased from Harlan Sprague-Dawley Inc. were 
used in this study. Twenty-eight pregnant rats were randomly assigned 
to the NP, NP rAgt-targeting siRNA, RUPP, or RUPP rAgt-targeting siR-
NA group. On day 12 of gestation, siRNA was injected s.c. into rats (10 
mg/kg). On gestational day 14, under isoflurane anesthesia, NP rats 
assigned to one of the RUPP groups underwent a reduction in uterine 
perfusion pressure (RUPP) (described in detail in Supplemental Meth-
ods). Animals were instrumented, and arterial pressure was determined 
in all groups of rats at day 19 of gestation as described previously (70).
All experimental animals were sacrificed on day 19 (RUPP mod-
el) or 21 (transgenic model). The fetuses and organs were removed, 
weighed, and collected. All surgery was performed under isoflurane 
anesthesia, and all efforts were made to minimize suffering.
Urinary rat albumin was measured with a commercially available 
ELISA (CellTrend). Serum cystatin C was measured with a commer-
cially available ELISA (BioVendor), and serum creatinine was deter-
mined by an automated clinical method. Serum PLGF (R&D Systems) 
and sFLT (MyBiosource) concentrations were measured with a com-
mercially available ELISA. Plasma PGE2 concentrations were mea-
sured with a commercially available ELISA (R&D Systems).
siRNA quantification assay. Maternal liver, fetal liver, and placenta 
levels of hAGT-targeting siRNA were quantified via stem loop quantitative 
reverse transcriptase PCR (qRT-PCR). In short, aliquots of the tissues (fro-
zen, powderized) were reconstituted to 100 mg/mL in PBS with 0.25% 
Triton X-100 and lysed by boiling. Further dilution of samples on a naive 
background matrix was made when the concentration of the siRNA might 
be expected to exceed the upper limit of quantification. The obtained 
supernatant subsequently was used to generate antisense-specific cDNA 
using a sequence-specific stem loop cDNA primer (GTCGTATCCAGTG-
CAGGGTCCGAGGTATTCGCACTGGATACGACtgagaa).
Antisense strand levels were quantified using a sequence-specific 
TaqMan assay and LightCycler 480 system (Roche). The TaqMan assay 
components were a forward primer (GCTGTTAAAACCCAATTTTTGT), 
reverse primer (GTGCAGGGTCCGAGGT), and probe (6FAM-TC-
CGAGGTA/ZEN/TTCGCACTGGAT–Iowa Black FQ). siRNA con-
centration was determined by interpolation from the standard curves 
generated by spiking of various concentrations of the siRNA in the naive 
tissue and processed as described above. The lower limit of quantitation, 
defined as 2 standard deviations above background, was 1.3 ng/g tissue.
Measurement of AGT and angiotensin II levels. hAGT and rAGT 
as well as angiotensin (Ang) peptide levels in the serum were mea-
sured by Attoquant Diagnostics GmbH, using mass spectrome-
try to investigate Ang metabolites. This technique allows for mea-
surement of 10 metabolites, including Ang 1-10 (Ang I), Ang 1-8 
(Ang II), Ang 1-7 (MAS receptor agonist), Ang 2-8 (Ang III), and 
Ang 3-8 (Ang IV). Samples were spiked with 100 pg/mL stable- 
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